UnknownNCT05637879
Glecaprevir/Pibrentasvir for PTSD
Medication studyAges 19–70United States
Understand this study
Who could participate?
This study is for people with PTSD. Listed age limits: 19 years to 70 years. Other eligibility criteria apply.
- Listed locations
- White River JunctionSee all locations and recruitment
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: December 18, 2023
- Recruitment status
- Unknown
- Enrollment listed in the registry
- 92
- Sponsor
- White River Junction Veterans Affairs Medical Center
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States
- Age range
- From 19 Years to 70 Years
- Official registry ID
- NCT05637879
- Official title
Show the full official title
Randomized Controlled Trial of Glecaprevir/Pibrentasvir for the Treatment of Post-traumatic Stress Disorder
Recruitment & locations
Status unknownThis badge reflects the study status reported by the registry. Check the registry for the latest information.
White River Junction
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is White River Junction Veterans Affairs Medical Center, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including Glecaprevir/pibrentasvir.
Who can participate?
This study is for people with PTSD. Listed age limits: 19 years to 70 years. Other eligibility criteria apply.
